Small molecule · developed by Oragenics
A non-natural synthetic neurosteroid enantiomer, described as a new chemical entity. It is being studied in mild traumatic brain injury and concussion.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06870240 | Phase 2 | Mild Traumatic Brain Injury, Concussion | Not yet recruiting | OGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mild Traumatic Brain Injury, Concussion
Updated Oct 25, 2026. Something wrong or missing? Report it on the OGEN page.
See OGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OGEN catalysts and pipeline →